Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

D.WESTERN THERAPEUTICS INSTITUTE

Q2 FY12/24

Financial Results Briefing Materials

August 9, 2024

D. Western Therapeutics Institute, Inc.

n Western Th

Stock Code: 4576

Table of Contents

- 1. Q2 FY12/24 Financial Results
- 2. Progress of Business in FY12/24
- 3. FY12/24 Forecast

(Reference) Business Overview




1. Q2 FY12/24 Financial Results

January 1 – June 30, 2024



Consolidated Statement of Income (YoY comparison)



Net sales

Net sales were up 19.1% YoY, due to strong royalties

Royalties for GLANATEC[®] declined, but royalties for GLA-ALPHA[®] grew steadily, royalties for GLANATEC FAMILY rose <u>13.3% YoY</u>. Royalties for DW-1002 rose <u>20.4% YoY</u>, due to the yen depreciation.

R&D expenses

R&D expenses rose <u>76.9% YoY</u> due to increased spending on development of H-1337 (Phase IIb study in the U.S.) and DWR-2206.



Consolidated Statement of Income (vs. full-year forecast)

			FY	12/24				
		1H results	FY results	1H results	YOY change	FY forecast (out Feb.13)	Progress	Primary factors
Ne	t sales	187	428	223	35	400	55.9%	 Storong royalties for DW-1002 and GLANATEC FAMILY
SG	&A expenses	431	1,190	654	223			
	R&D expenses	294	930	521	226	1,600	32.6%	 Development expenses for H-1337 was less than expected. It will be expensed upon completion
	Other SG&A expenses	136	259	133	(3)			
Ор	erating loss	(258)	(798)	(449)	(191)	(1,500)	-	
Ordinary loss		(254)	(796)	(459)	(204)	(1,510)	-	
Loss attributable to owners of parent for the interim period		(247)	(812)	(520)	(272)	(1,510)	_	 Loss on redemption of convertible bonds of JPY60mn in extraordinary losses



(JPYmn)

Consolidated Statement of Income

	ne 30, 2024 to December 31, 2023) Current liabilities 95 (-98)	 Cash and deposits Declined due mainly to R&D expenditures Funding for immediate business development activities is secured., supported in part by the exercise of Series 12 Stock Acquisition Rights
Cash and deposite		Supplies ➢ JPY260mn increase in advance payments to suppliers due to H-1337 development Non-current assets
Cash and deposits 1,301 (-566)	Non-current liabilities 1,113(+214)	 > JPY20mn in amortization of intangible assets related to the licensing agreement for DW-1002 (Europe) Current liabilities > JPY112mn decline in accounts payable due to H-1337 and DWR-2206 development costs > JPY9mn increase in current portion of long-term borrowings Non-current liabilities
Accounts receivable trade123 (+6)Other current assets423 (+269)Non-current assets217 (-17)	Net assets 856(-423)	 > JPY160mn increase in long-term borrowings due to loans to fund the development of DWR-2206 > JPY53mn increase due to difference between issuance of bonds payable of JPY660mn and redemption of convertible bonds of JPY60mn Net assets > Recorded a loss attributable to owners of parent of JPY520mn > Recorded JPY45mn each in capital and capital reserves due to exercise of stock acquisition rights

Consolidated Cash Flow Statement



Cash flow from operating activities

JPY519mn outflow due to the recording of loss before income taxes, JPY260mn due to increase in advance payments to suppliers

Cash flow from investing activities

> JPY8mn outflow from acquisition of property, plant and equipment

Cash flow from financing activities

- JPY660mn proceeds from issuance of bonds, JPY170mn proceeds from long-term borrowings, JPY65mn proceeds from the exercise of stock acquisition rights
- > JPY666mn redemption of convertible bonds

<u>On-hand liquidity on June 30, 2024 consisted only of JPY1.3bn in cash and deposits (no securities)</u>

[Exercise status of Series 12 Stock Acquisition Rights]

- ✓ Number of shares exercised 900,000 (6.9%)
- ✓ Total amount raised JPY80mn

(As of June 30, 2024)



Issuance of Unsecured Corporate Bonds (Private Placement) and Series 12 Stock Acquisition Rights (Announced on May 17, 2024)

Series 1 Convertible Bonds JPY606mn	Corporate Bonds JPY660mn	 Redeem convertible bonds with funds raised from corporate bonds Cancel Series 11 Stock Acquisition Rights and issue Series 12 Stock Acquisition Rights
Series 11 Stock Acquisition Rights 13,990 units remaining (1.3mn shares)	Series 12 Stock Acquisition Rights 13mn new shares (dilution ratio: 40%)	 Change from fixed to variable exercise price to facilitate fundraising Cantor, the allottee, will sell the company shares to foreign institutional investors off-market, hence the sales will have little impact on the share price
Total funds raised JPY1.0bn	Total funds to be raised JPY1.4bn	 ✓ No stock lending ✓ Funds raised as of July 31, 2024: JPY313mn (ratio of stock acquisition rights exercised: 29.2%)

(Use of funds for Series 12 Stock Acquisition Rights

Specific use of funds	Amount (JPYmn)	Expected timing of expenditure
Development funds for H-1337	400	March 2025–December 2027
② Funds for drug discovery research (including joint research) and acquisition of new pipelines/ funds for promoting development	200	October 2024–December 2027
3 Bond redemption funds (Series 1 Unsecured Convertible Bonds with Stock Acquisition Rights)	660	7 June 2024
Working capital	167	January 2025–December 2027

2. Progress of Business in FY12/24



Development Pipeline in 2024 1H

prod	lucts on m	narket	Regio	on				С	urrent state		
GLANATE	$C^{\mathbb{R}}$ (Single	drug)	Japan, J	Asia	Decrease	slightly d	lue to laun	ich of coi	mpounded drugs		
GLA-ALPH	┨A [®] (Comb	ination drug)	Japa	n	Launched in December 2022, Strong s						
DW-1002	(Single drug)	Europe,	U.S.	Strong du	e to yen o	depreciatio	on			
DW-1002	(Combinatio	n drug)	Europe,	etc.	Strong du	e to yen o	depreciatio	on			
Produ	ucts	Region	Non-clinical	P-I	P-II	P-III	Application	Approval	Current state		
K-321		U.S., etc.							Global Phase III ongoing		
	Combination	U.S.									
DW-1002		China							Regulatory review underway		
	Single	Japan							Negotiations with the regulatory authority and examination underway for application filing		
DW-1001		Japan									
H-1337		U.S.							Phase IIb ongoing		
DW-5LBT		U.S.							Reapplied in January 2024, received CRL in July		
DWR-2206	_					-10			Submitted a Clinical Trial plan Notification for Phase II in March		

2-1. Successful launch (commercialization)





Glaucoma Treatment Ripasudil hydrochloride hydrate

リラナテック

(JPYmn)

Royalties for GLANATEC FAMILY (Single drug · Combination drug) 200 GLA-ALPHA[®] Launched 100 0 2020 2021 2022 2023 2024 H1

- ✓ GLA-ALPHA[®], steady progress to date
- ✓ GLANATEC[®] royalties are scheduled to end in September 2024.
 ⇒Overall royalties are on the decline

GLANATEC® Ophthalmic Solution 0.4%

- ✓ The company expects to receive royalties for the single agent for up to September 2024.
- To receive royalties a little overseas

GLA-ALPHA® Combination ophthalmic solution

Combination drug with ripasudil hydrochloride hydrate and brimonidine tartrate

- ✓ Significant YoY increase
- ✓ Overseas expansion(Filed in Thailand in December 2023 and in Singapore in February 2024. Applications for other Asian countries are in preparation.)
- ✓ Japan: Sales projected to peak at JPY8.1bn (Kowa Co., Ltd. sales) (Ten years following launch; 230,000 patients)

Japanese Market

- FY2021: about 80.8 billion yen
- Use of combination drug is on the rise



Copyright D. Western Therapeutics Institute, Inc. All Rights Reserved.


Ophthalmic Surgical Adjuvant DW-1002 (Brilliant Blue G)

Charact

eristics

Charact

eristics



ILM-Blue[®], TissueBlue[™]

Ophthalmic surgical adjuvant with Brilliant Blue G, a dye with excellent staining ability, as the active ingredient

- Enables visualization of the internal limiting membrane (thinness: approx. 0.003mm)
- Used in vitrectomy for the treatment of diabetic retinopathy, macular hole, etc.

MembraneBlue-Dual®

Combination of Brilliant Blue G and Trypan Blue

- Stains internal limiting membrane, epiretinal membrane, and proliferative membrane in proliferative vitreoretinopathy
- Used during vitrectomy, such as proliferative vitreoretinopathy, etc.

Presumed number of surgeries



✓ Strong sales

+20.4% YoY change increase due to yen depreciation

 Plan to launch Single drug in China and Japan, Combination drug in the U.S.

Expects a substantial increase in royalties

2-2. Development Pipeline



Development Pipeline

F	Products	Clinical indication	Region	Non- clinical	P-I	P-II	P-III	Application	Approval	Launch	Licensee
K-321	Ripasudil hydrochloride hydrate	Fuchs endothelial corneal dystrophy	U.S., etc.								Kowa
		II M steining	China								DORC
DW-1002	Brilliant Blue G (BBG)	ILM staining	Japan								Wakamoto
DW-1002		ALC staining	Japan								Pharmaceutical
	BBG/ Trypan blue	ILM staining and ERM staining	U.S.								DORC
DW-1001		Ophthalmic treatment agent (undisclosed)	Japan								ROHTO Pharmaceutical
H-1337		Glaucoma and ocular hypertension	U.S.								Developed internally
DW-5LBT		Neuropathic pain after shingles	U.S.								Jointly developed with MEDRx
DWR-2206		Bullous keratopathy	Japan								Joint development with ActualEyes

• • • ophthalmology pipeline



Fuchs Endothelial Corneal Dystrophy K-321

→Global Phase III ongoing


Expansion of indications

Ripasudil hydrochloride hydrate

- ✓ Global Phase III studies commenced in March and April 2023
- ✓ After going on sale, to receive royalties until end of data protection period*

*Patent royalty rate differs from that of single agent

Phase III study



*1: Obtained by multiplying the population over 40 estimated by the Company based on the United Nations' "World Population Prospects 2022" by the morbidity rate of 4% (*2)
*2: Moshirfar M et al., Fuchs Endothelial Dystrophy. Treasure Island (FL): StatePearls Publishing; 2021

Identifier*	NCT05528172 study completed	NCT05795699	NCT05826353		
Summary	Administration to patients after cataract surgery	Administration to patients with FECD after descemetorhexis	Administration to patients with FECD after simultaneous cataract surgery and descemetorhexis		
No. of patients	331	100	100		
Study period	August 2022–June 2023	March 2023–January 2025	April 2023–January 2025		
Development region	U.S.	U.S., Europe, etc.	U.S., Europe, etc.		

*ClinicalTrials.gov Identifier from https://www.clinicaltrials.gov



Ophthalmic Surgical Adjuvant DW-1002

Consultation with PMDA ongoing toward marketing application submission

Single drug China, Japan


- ✓ China: Marketing application filed in May 2023, treated as a medical device
- ✓ Japan: Issues related to standards and quality in the use of U.S. approved data
 - ⇒Aiming to apply in FY2024, but depending on the status of consideration, the development plan may be affected.

Combination drug U.S.

✓ Obtained orphan drug designation from the U.S. FDA in July 2023. Preparing for application.

Development plan

Clinical indication	Region	Licensee	P-III	Application	Approval	Launch
ILM staining	China	DORC		2023	20	24
ILM staining, ALC staining	Japan	Wakamoto Pharmaceutical(*)		2024	20	25
ILM staining and ERM staining	U.S.	DORC		2025	20	26



*1: DWTI estimate (based on interviews with related parties, etc.)
*2: June 2019 data of MHLW's Statistics of Medical Care Activities in Public Health Insurance, 2019

*Based on our forecast

Glaucoma Treatment H-1337 First Choice as Second-Line Drug

→Phase IIb study ongoing in U.S.

Internally developed products



- Confirmed safety and efficacy in Phase I/IIa studies (clinical POC obtained, p < 0.0001)
- Charact eristics
- Facilitates drainage of aqueous humor through the trabecular meshwork and Schlemm's canal
- Multikinase inhibitor effective on various types of protein kinases

[State of Progress]

- ✓ Patient administration started in August
- ✓ No change in plan, although it took time to patient inclusion
- No new recruitment planned; patient registration largely complete

➔Top line data to be released in late 2024.


Phase IIb trial design

Overview:

 Multi-center, randomized, double-blind, activecontrolled, dose-finding study to determine efficacy and safety of H-1337 as a treatment for patients with glaucoma and ocular hypertension.

Planned number of patients	200
Dosing period	28 days
Dosage and administration	H-1337 (0.6%), H-1337 (1.0%) Timolol: Eye drops administered twice a day H-1337 (1.0%): Eye drops administered once a day
Primary endpoints	Compare intraocular pressure reduction effect of H-1337 versus Timolol
Secondary endpoints	Evaluation of ocular and systemic safety

H-1337 Marketability and Development Plan



*1 :Classified and compiled by DWTI based on IQVIA MIDAS Dec 2020 MAT Reprinted with permission

*2 : Calculated by DWTI based on Journal of Managed Care & Specialty Pharmacy, Vol. 25, No. 9 September 2019, 1001-1014

Standard treatments for glaucoma

- Prostaglandin analogues (PGs) demonstrate the strongest IOP-lowering effect among first-line drugs; generic drugs are available and are most frequently used
- PGs also have little to no effect on many patients, and more than half of drug-treated patients use multiple medications
 - ➔ Needs for new drugs that are different in action from PGs, and have sufficient efficacy and high safety

[Development Plan]

	P-I/IIa	P-	P-III	
U.S.		2023	2024	2025 or later

- ✓ Toxicity studies required at the start of PIII are being conducted to start a smooth start of PIII
- PIII policy (in-house development or out-licensing) is under consideration



Regenerative Cell Therapy DWR-2206

Submitted a Clinical Trial plan Notification for Phase II in Japan

Joint development product

∕ <u>→</u> ActualEyes

Cultured corneal endothelial cells

+ ROCK inhibitor

Targeting bullous keratopathy, cultured human corneal endothelial cells and a suspension containing ROCK inhibitor are injected into the anterior chamber of the eye to regenerate corneal endothelium

> Warmed to thaw, and injected



Frozen corneal endothelial cell preparation

[State of Progress]

✓ Submitted a Clinical Trial plan Notification in March
 →Preparations underway, including patient screening

Phase II trial design

Published on jRCT on June 11, 2024 (jRCT2043240040)


<u>Overview:</u>

 Multi-center, open-label, uncontrolled study to determine the safety and efficacy of DWR-2206 in patients with bullous keratopathy

Target number of patients	6
Evaluation and monitoring period	48 weeks after transplantation of the investigational product
Primary endpoints	Number of cases and incidence rate (%) of adverse events and adverse events that cannot be ruled out as related to the investigational product
Secondary endpoints	 Monitoring and evaluation of safety endpoints Number and incidence rate (%) of significant adverse events Improvement in visual acuity at 24 weeks after transplantation of the investigational product Change in best corrected visual acuity over time Change in corneal thickness over time Change in corneal endothelial cell density over time



DWR-2206 Marketability and Development Plan



Reason why new treatment is sought

Only treatment for bullous keratopathy is a corneal transplant, which has the following challenges.

- Donor shortage
- Highly skilled surgeon and sophisticated equipment required for surgery
- Risks include infection, astigmatism, rise in intraocular pressure, and adhesion failure of transplant.

Development Plan

	Non-clinical			P	P-III		
Japan		2023		2024	2025		2026

 The rights for Greater China and Korea have already been licensed to Arctic Vision by the originating company, ActualeEyes

(Reference) Competitors of DWR-2206

	Cultured human		
L	corneal endothelial cells	Magnetic nanoparticle-loaded cultured human corneal endothelial cells	iPS cell-derived human corneal endothelial cells as an alternative to donor corneal endothelium
by (Aurion (U.S.)/CorneaGen Japan	Emmecell (U.S.)	Cellusion
ent stage	Japan : Approval U.S. : Phase I / Phase II	U.S. : Phase I	Global : Phase I

Neuropathic Pain Treatment DW-5LBT

→Received CRL, analyzing the data for reapplication.



Lidocaine patch products for a treatment for neuropathic pain after shingles




- Confirmatory comparative (bioequivalence) clinical trial comparing DW-5LBT with innovator product Lidoderm[®] generated favorable results
- Low dermal irritation
- Excellent adhesive strength
- Capable of maintaining adhesive strength during exercise

[State of Progress]

- ✓ Reapplied in January 2024
- Received Complete Response Letter (CRL) in July 2024.

\rightarrow Plan to conduct additional analysis and reapply

for reapplication.



[Development Plan]

	Reapply	Approval	Launch
U.S.	2024		



3. FY12/24 Forecast




Expansion of business domain

Medium-term management plan (2020–2024)

Increase number of pipeline products and undertake later-stage clinical development


Enhancement of development pipeline and

<u>indicator</u> Increase in the number of units in the development pipeline



Initiatives in 2024

Initiatives in 2024, the final year of the medium-term management plan





Management themes

H-1337	Publish top-line data of Phase IIb study in US		
DW-5LBT	U.S. reapplication \sim Approval, Launch $$ Received CRL		
DWR-2206	Start of Phase II study in Japan <a>A achieved achieved in March		
DW-1002	Application, approval and Launch in China, Application in Japan		
New projects	Research progress (including new collaborations)		



Consolidated Earnings Forecast for FY12/24 (released February 9, 2024)

(JPYmn)

	FY12/23	FY12/24 FY forecast YoY change		
	FY results			Primary factors
Net sales	428	400	(28)	 Royalty income from GLANATEC[®] will end, but sales of DW-1002 are expected to increase. The main breakdown is as follows. Royalty income: DW-1002 (Europe, US, China, etc.), GLANATEC[®], GLA-ALPHA[®] Milestone revenue: DW-1002 (Japan)
Operating loss	(798)	(1,500)	(702)	 Increase in R&D expenses Other SG&A expenses are expected to be approximately the same as the previous year.
Ordinary loss	(796)	(1,510)	(714)	
Loss attributable to owners of parent	(812)	(1,510)	(698)	

R&D expenses	930	1,600	670	 Increase expenses to prepare for Phase III clinical trials of H-1337 in the U.S. Increase expenses for R&D activities to create new drugs(In-house drug discovery and collaborative research).
--------------	-----	-------	-----	---

Fund procurement through the issue of stock acquisition rights ongoing (until June 3, 2027)


Development Pipeline Plan

Products	and Clinical indication	Region	2023	2024	2025	2026
H-1337	Glaucoma and ocular hypertension	U.S.		P2b	P3	*2025 or later
K-321	Fuchs endothelial corneal dystrophy	U.S.		P3		Application
DW-5LBT	Neuropathic pain after shingles	U.S.		Re-application Approval	L	aunch
DW-1001	Ophthalmic treatment agent	Japan			P2	
	ILM staining	China	Application	Approval	Lau	nch
DW-1002	ILM staining ALC staining	Japan		Application	Approval	Launch
	ILM staining and ERM staining	U.S.	Appli	cation preparation	Application	Approval Launch
DWR-2206	Bullous Keratopathy	Japan	Nonclinical	P2		P3


Note: Development plans are based on development plans of the licensees or our forecast. Hence, actual development progress may differ from that plan.

DWTI

Investment in Growth and Securing Base Revenue



Our Ongoing Growth Cycle





(Reference) Business Overview




DWTI Overview / History

Name	D. Western Therapeutics Institute, Inc. (DWTI)		4000	
Markets	Tokyo Stock Exchange Growth Market (Code : 4576)	Focus on basic research	1999	Founded of a company
Business	New drug discovery, research, and development		2006	Established R&D laboratory (Mie University)
Capital	JPY877mn		2009	Listed on Tokyo Stock Exchange Growth Market
Officers and Employees	33 (connection)		2014	Launch in Japan of internally developed products
	Head office : Nagoya-shi, Aichi, Japan			internally developed products
Location	R&D laboratory : Tsu-shi, Mie, Japan (Established Institute of Human Research	Expansion of business domain	2015	Started of In-licensed products developed by other companies
	Promotion and Drug Development at Mie University)	-Undertaking internally development	2018	Started of internally clinical development
Consolidated Subsidiary	Japan Innovative Therapeutics, Inc. Japan Innovative Therapeutics	-Collaboration with other companies	2022	Started of jointly development of regenerative medicine products

As of June 30, 2024 31



Business Highlights



- Four products available on the market
- Five products in late stages of development (Phase III study or later)



- About 1,500 kinase inhibitors included in DWTI's compound library
- A pioneer in the field of kinase inhibitors



- Out-licensed seven products
- Internally developing Three additional products (including joint development)

Our Businesses

Drug Discovery	Internal drug discovery	 Create promising kinase inhibitors from our original compound library with efficiency Create new drug seeds by collaborating with other companies
Drug Development Busines	Clinical development	✓ Internal clinical development (including the evaluation of safety and efficacy in humans)
	Business development	 Out-licensing activities for original products and in-licensed products Consider in-licensing of products in late development stages and repurposed drugs

Core Technologies to Create New Drugs

- DWTI's drug discovery engine is an original core technology that enables us to continuously create new drugs
- A kinase is an enzyme that phosphorylates proteins; excessive phosphorylation is a factor that contributes to the onset of various diseases (kinases regulate protein activity)

Drug discovery engine

Compound library

- ✓ <u>Superior new drug seeds</u>
- ✓ Includes three launched drugs

Drug design

 ✓ Ability to create new drugs from compounds in our library (experience, data)

Drug-Western Method

- \checkmark Tool for exploring mechanisms of action of new drugs
- Enhance value by estimating mechanisms (estimate safety and elements of therapeutic effects)

Potential uses of kinase inhibitors

Various indications

- ✓ Kinases play a critical role in a variety of diseases
- Kinase inhibitors are primarily used in anti-cancer agents; development of kinase inhibitors to treat immune, neurodegenerative, and inflammatory diseases is also under consideration

Large market scale

✓ Total annual sales of kinase inhibitors exceed JPY2tn

DWTI is a pioneer in the field of kinase inhibitors

 ✓ Launched in 1995, fasudil is the world's first kinase inhibitor (and is included in our compound library)





Innovative New Drugs to the World from Japan

D. Western Therapeutics Institute



- These materials have been created with the goal of facilitating understanding regarding the company and were not produced for the purpose of soliciting investment in the company.
- Earnings forecasts and projections regarding future events included within these materials are based on determinations made by the company using information that was available at the time at which these materials were produced and are therefore subject to impact from potential risks and uncertainties. Consequently, actual results may differ significantly from these forecasts and projections due to a variety of factors, including changes in business environment.
- Information related to other companies included in these materials has been taken from publicly available information and other sources. The company has not verified the accuracy or suitability of this information and therefore provides no corresponding guarantees.

D. Western Therapeutics Institute, Inc.

